Association of EGFR gene G719S and T790M mutations with cervical cancer.
10.3760/cma.j.issn.1003-9406.2019.04.021
- VernacularTitle:EGFR基因G719S和T790M突变与宫颈癌的相关性研究
- Author:
Huahua XIANG
1
;
Jing ZHOU
1
;
Hua PENG
1
;
Weilei DONG
2
;
Yongqing GONG
1
;
Hongquan ZHANG
1
;
Zifen GUO
1
Author Information
1. Institute of Pharmacy and Pharmacology, Hunan Provincial Cooperative Innovation Center for Molecular Target New Drug Research, University of South China, Hengyang, Hunan 421001, China. Email: guozifen@aliyun.com.
2. Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Drug Resistance, Neoplasm;
ErbB Receptors;
genetics;
Female;
Genes, erbB-1;
Humans;
Lung Neoplasms;
Mutation;
Protein Kinase Inhibitors;
Uterine Cervical Neoplasms;
genetics
- From:
Chinese Journal of Medical Genetics
2019;36(4):376-379
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To establish a rapid and accurate "on/off" switch technique consisted of 3'-phosphorothioate-modified allele-specific primers and exo+ polymerase to screen the G719S and T790M mutations of epidermal growth factor receptor (EGFR) gene. The switch was used to identify cervical cancer patients who are sensitive to tyrosine kinase inhibitor (TKI).
METHODS:Allele-specific primers targeting recombinant wild-type and mutation-type templates were designed with 3' terminal phosphorothioate modification. Two-directional primer extension was carried out using Pfu polymerase. The G719S and T790M mutations were detected by the technique among cervical cancer tissues. The results were verified by Sanger sequencing.
RESULTS:No mutation was detected among the 80 cervical cancer cases, and the results were consistent with that of Sanger sequencing. No significant difference was found between the frequencies of the G719S and T790M mutations between the patient and the control groups (P> 0.05).
CONCLUSION:A sensitive "on/off" switch technique for detecting the two EGFR mutations was established. The G719S and T790M mutations are not associated with cervical cancer.
